PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 182 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $3,450,000 | +53.9% | 72,334 | +47.2% | 0.02% | +50.0% |
| Q1 2017 | $2,241,000 | +186.2% | 49,134 | +102.6% | 0.01% | +200.0% |
| Q4 2016 | $783,000 | +4.4% | 24,255 | +10.6% | 0.00% | 0.0% |
| Q3 2016 | $750,000 | -60.5% | 21,921 | -61.1% | 0.00% | -60.0% |
| Q2 2016 | $1,901,000 | +121.3% | 56,351 | +247.6% | 0.01% | +100.0% |
| Q1 2016 | $859,000 | -13.4% | 16,211 | +25.4% | 0.01% | 0.0% |
| Q4 2015 | $992,000 | +249.3% | 12,923 | +87.3% | 0.01% | +400.0% |
| Q3 2015 | $284,000 | -96.1% | 6,900 | -91.6% | 0.00% | -96.4% |
| Q1 2015 | $7,319,000 | +23.0% | 82,380 | +22.8% | 0.03% | +16.7% |
| Q4 2014 | $5,948,000 | -1.2% | 67,088 | +8.0% | 0.02% | -4.0% |
| Q3 2014 | $6,023,000 | -57.5% | 62,139 | -59.8% | 0.02% | -55.4% |
| Q2 2014 | $14,183,000 | +1084.9% | 154,393 | +802.9% | 0.06% | +1020.0% |
| Q1 2014 | $1,197,000 | +220.9% | 17,100 | +163.3% | 0.01% | +150.0% |
| Q4 2013 | $373,000 | – | 6,495 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |